BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $228,000 | -97.9% | 2,940 | -97.8% | 0.02% | -97.8% |
| Q2 2021 | $10,695,000 | -27.8% | 132,858 | -24.4% | 0.69% | -37.9% |
| Q1 2021 | $14,819,000 | +3.4% | 175,701 | -1.6% | 1.10% | +3.8% |
| Q4 2020 | $14,334,000 | +0.4% | 178,648 | +0.7% | 1.06% | -12.4% |
| Q3 2020 | $14,272,000 | -7.0% | 177,467 | -0.4% | 1.22% | -13.9% |
| Q2 2020 | $15,348,000 | +4.0% | 178,265 | -1.9% | 1.41% | -13.0% |
| Q1 2020 | $14,753,000 | -8.9% | 181,706 | -6.2% | 1.62% | +2.5% |
| Q4 2019 | $16,193,000 | +12.2% | 193,644 | +17.3% | 1.58% | +4.0% |
| Q3 2019 | $14,435,000 | +9.2% | 165,027 | +2.3% | 1.52% | +8.5% |
| Q2 2019 | $13,213,000 | +20.9% | 161,336 | +20.0% | 1.40% | +11.1% |
| Q1 2019 | $10,929,000 | +64.8% | 134,416 | +33.4% | 1.26% | +43.7% |
| Q4 2018 | $6,632,000 | +1114.7% | 100,757 | +1322.5% | 0.88% | +1271.9% |
| Q3 2018 | $546,000 | -10.5% | 7,083 | -14.4% | 0.06% | -16.9% |
| Q2 2018 | $610,000 | – | 8,271 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |